macrocycles

business targets illustration
Biotech

Argenx's $1.5B pact to turn macrocyclic peptides to new targets

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Unnatural Products.
James Waldron Jul 1, 2025 8:00am
gym

Macrocyclic peptides preserve muscle in mice given semaglutide

Dec 12, 2024 12:45pm
beach sea tide waves

Merck & Co. signs $220M macrocyclic peptide deal

Jan 23, 2024 9:00am